Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 27, 2026, titled "Press Release on approval of Buy- Back of Equity shares of the Company.".
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jagsonpal Pharmaceuticals has received shareholders' approval for its proposed buyback of equity shares. The Board had earlier proposed on March 12, 2026 to buy back up to 16 lakh (1.6 million) equity shares at Rs. 250 per share, aggregating up to Rs. 40 Crores. The company says the buyback aims to optimise capital allocation, improve earnings per share (EPS), and deliver returns to shareholders. The result of the shareholders' vote was announced on April 27, 2026. Further details including timelines and the record date will be shared later as per regulations.
The buyback at Rs. 250 per share is a positive signal for shareholders, as it represents a capital return and should boost EPS by reducing the share count. Short-term price support is likely near the buyback price, though actual impact will depend on the record date and execution timeline.